Method for detecting risk of alzheimer's disease
AssigneeMagqu Co. Ltd.
InventorSHIEH-YUEH YANG
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for detecting the risk of Alzheimer's disease, comprising detecting immunomagnetic reduction signals of two biological markers in a biological sample from a subject, wherein the two biological markers is tau protein and Aβ-42 protein, respectively; and calculating concentrations of the above two biological markers and using the product of the concentrations of the above two biological markers to diagnosing the risk of Alzheimer's disease, wherein the concentration is calculated by the conversion of the magnetic reduction signals.
Claims11
A method for detecting the risk of Alzheimer's disease, comprising:
- (a) detecting in vitro immunomagnetic reduction (IMR) signals of two Alzheimer's disease biomarkers in a biological sample of a subject, wherein the IMR signals are produced by the two Alzheimer's disease biomarkers binding with magnetic nanoparticles containing an anti-Alzheimer's disease biomarker antibody, wherein the two Alzheimer's disease biomarkers are tau protein and Aβ-42 protein respectively;
- (b) the IMR signals of the two Alzheimer's disease biomarkers detected in step (a) are fitted to a logistic function (I) to calculate each Alzheimer's disease biomarker's concentration in the biological sample:
- I
-
-
- M
-
-
- R
-
- (
- %
- )
- =
- A
- -
- B
- 1
- +
- (
- φ
- φ
- o
- )
- γ
- +
- B
- (
- I
- )
- wherein IMR(%) is the IMR signals of the Alzheimer's disease biomarker, φ is the concentration of the Alzheimer's disease biomarker, fitting parameter A is a background value, B is a maximum value, φ0 is the concentration of the biomarker when IMR signal equals ((A+B)/2), γ is a slope at data point φ0 of a curve where φ is x-axis and IMR(%) is y-axis;
- and
- (c) comparing a product of the two Alzheimer's disease biomarkers' concentration obtained in step (b) to a standard value calculated by multiplying two Alzheimer's disease biomarkers' concentrations, when the product of two Alzheimer's disease biomarkers' concentration is higher than the standard value that is indicative of the increasing risk of Alzheimer's disease of the subject.
Dependencies are inferred from the claim text.